CL2019000420A1 - Preparación farmacéutica anti-envejecimiento. - Google Patents

Preparación farmacéutica anti-envejecimiento.

Info

Publication number
CL2019000420A1
CL2019000420A1 CL2019000420A CL2019000420A CL2019000420A1 CL 2019000420 A1 CL2019000420 A1 CL 2019000420A1 CL 2019000420 A CL2019000420 A CL 2019000420A CL 2019000420 A CL2019000420 A CL 2019000420A CL 2019000420 A1 CL2019000420 A1 CL 2019000420A1
Authority
CL
Chile
Prior art keywords
liquid
stage
production method
pharmaceutical preparation
container
Prior art date
Application number
CL2019000420A
Other languages
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/001888 external-priority patent/WO2017080669A1/en
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of CL2019000420A1 publication Critical patent/CL2019000420A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)

Abstract

UNA PREPARACIÓN FARMACÉUTICA PARA SU USO POR INYECCIÓN EN LA PIEL, DONDE LA PREPARACIÓN FARMACÉUTICA SE PUEDE REALIZAR MEDIANTE UN MÉTODO DE PRODUCCIÓN QUE INCLUYE LAS ETAPAS DE PROPORCIONAR UN LÍQUIDO EXTRAÍDO DE UN ORGANISMO, CUYO LÍQUIDO CONTIENE CONSTITUYENTES CELULARES DE LA SANGRE, PROPORCIONANDO UN RECIPIENTE O MEDIO DE CONTENCIÓN. DICHO RECIPIENTE O MEDIO DE CONTENCIÓN TIENE UNA SUPERFICIE INTERNA Y HACE CONTACTO CON DICHO LÍQUIDO CON DICHO RECIPIENTE O MEDIO DE CONTENCIÓN, DONDE A) DICHO MÉTODO DE PRODUCCIÓN INCLUYE ADEMÁS LA ETAPA DE INCUBAR DICHO LÍQUIDO EN DICHO RECIPIENTE O MEDIO DE CONTENCIÓN DURANTE UN TIEMPO DE INCUBACIÓN Y OPCIONALMENTE RETIRAR LOS COMPONENTES CELULARES DE DICHO LÍQUIDO DESPUÉS DE DICHA INCUBACIÓN, B) DICHO LÍQUIDO CONTIENE EXOSOMAS Y DICHO MÉTODO DE PRODUCCIÓN CONTIENE ADEMÁS LAS ETAPAS DE CONCENTRAR DICHOS EXOSOMAS Y OPCIONALMENTE RETIRAR LOS CONSTITUYENTES CELULARES DE DICHO LÍQUIDO DESPUÉS DE DICHA CONCENTRACIÓN, O LA ETAPA DE AISLAR DICHOS EXOSOMAS, O C) DICHO MÉTODO DE PRODUCCIÓN CONTIENE ADEMÁS LA ETAPA DE EVITAR LA INCUBACIÓN DE DICHO LÍQUIDO Y LA ETAPA DE RETIRAR LOS CONSTITUYENTES CELULARES DE DICHO LÍQUIDO QUE HACE CONTACTO CON DICHO RECIPIENTE O MEDIO DE CONTENCIÓN.
CL2019000420A 2016-08-17 2019-02-15 Preparación farmacéutica anti-envejecimiento. CL2019000420A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16001807 2016-08-17
PCT/EP2016/001888 WO2017080669A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders
PCT/EP2016/001887 WO2017080668A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders

Publications (1)

Publication Number Publication Date
CL2019000420A1 true CL2019000420A1 (es) 2019-07-05

Family

ID=61196401

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000420A CL2019000420A1 (es) 2016-08-17 2019-02-15 Preparación farmacéutica anti-envejecimiento.
CL2019000419A CL2019000419A1 (es) 2016-08-17 2019-02-15 Preparación farmacéutica anti-envejecimiento

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019000419A CL2019000419A1 (es) 2016-08-17 2019-02-15 Preparación farmacéutica anti-envejecimiento

Country Status (21)

Country Link
US (3) US20190290689A1 (es)
EP (4) EP3695845A1 (es)
JP (2) JP2019528281A (es)
KR (2) KR20190049690A (es)
CN (2) CN108348548A (es)
AU (2) AU2017313163B2 (es)
BR (1) BR112019002982A2 (es)
CA (2) CA3033045A1 (es)
CL (2) CL2019000420A1 (es)
CO (2) CO2019001232A2 (es)
CR (2) CR20190139A (es)
EA (2) EA201890841A1 (es)
HK (3) HK1258712A1 (es)
IL (2) IL259007B2 (es)
MA (2) MA42963A (es)
MX (2) MX2019001948A (es)
PE (2) PE20190627A1 (es)
PH (2) PH12019550017A1 (es)
SG (2) SG11201900866YA (es)
TW (2) TW201806606A (es)
WO (3) WO2018033226A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890841A1 (ru) * 2016-08-17 2018-09-28 Ортоген Аг Фармацевтический препарат против старения
CN108841784A (zh) * 2018-07-17 2018-11-20 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种含黄芪甲苷的髓核细胞抗衰老抗凋亡培养基
EP3613424A1 (en) * 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
WO2020138023A1 (ja) * 2018-12-27 2020-07-02 サントリーホールディングス株式会社 変性エラスチンの分解低下の抑制剤、正常なエラスチン線維の維持剤、エラスチン－エラフィン複合体形成抑制剤及びエラスチン－エラフィン複合体形成抑制作用を有する物質のスクリーニング方法
RU2695264C1 (ru) * 2018-12-27 2019-07-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Хакасский государственный университет им. Н.Ф. Катанова" (ФГБОУ ВО ХГУ им. Н.Ф. Катанова) Способ прогнозирования ускоренного старения организма женщин, основанный на клинических данных о состоянии репродуктивной функции
US12269003B2 (en) 2019-12-30 2025-04-08 Industrial Technology Research Institute Extracellular vesicle separation method, colloidal particle and preparation method thereof
US12077780B2 (en) 2020-02-14 2024-09-03 Allergan Sales, Llc Conditioned medium from cells cultured under hypoxic conditions and uses thereof
US20250186498A1 (en) * 2022-05-16 2025-06-12 Taiwan Mitochondrion Applied Technology Co., Ltd. Composition for hearing loss mitigation and use thereof
JP7624256B1 (ja) 2024-01-26 2025-01-30 万里 坂井 医薬組成物及びその製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070058441A (ko) * 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
DE102006005016A1 (de) * 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
WO2012076193A1 (de) * 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
AU2013302799B2 (en) * 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN103767985A (zh) * 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
KR101784050B1 (ko) * 2014-12-23 2017-10-10 영남대학교 산학협력단 엑소솜을 유효성분으로 함유하는 피부 노화 예방 또는 치료용 약학조성물
CN105477016A (zh) * 2015-11-13 2016-04-13 中国人民解放军第二军医大学 人间充质干细胞来源的外泌体在抗组织纤维化及瘢痕形成中的应用
WO2017080668A1 (en) * 2015-11-13 2017-05-18 Orthogen Ag Pharmaceutical preparation effective in age-related disorders
CN105505854B (zh) * 2016-01-14 2019-07-12 上海市第六人民医院 来源于人尿液细胞的外泌体的获取方法与应用
CN105582576B (zh) * 2016-02-23 2018-08-17 武汉大复生物科技有限公司 提高内皮祖细胞外泌体释放并促进骨缺损修复的生物材料、制备方法及用途
EA201890841A1 (ru) * 2016-08-17 2018-09-28 Ортоген Аг Фармацевтический препарат против старения

Also Published As

Publication number Publication date
CA3033045A1 (en) 2018-02-22
WO2018033226A1 (en) 2018-02-22
HK1255619A1 (zh) 2019-08-23
JP2019528281A (ja) 2019-10-10
EP3695845A1 (en) 2020-08-19
AU2017313164B2 (en) 2019-01-03
EP3352770A1 (en) 2018-08-01
WO2018033249A1 (en) 2018-02-22
EP3352769A1 (en) 2018-08-01
PE20190517A1 (es) 2019-04-10
EP3763377A1 (en) 2021-01-13
MA42963A (fr) 2018-08-01
IL259007A (en) 2018-07-31
BR112019002982A2 (pt) 2019-05-14
CO2019001232A2 (es) 2019-02-28
IL259007B1 (en) 2024-03-01
JP2019529357A (ja) 2019-10-17
BR112019002080A2 (pt) 2019-05-14
CN108348548A (zh) 2018-07-31
TW201806605A (zh) 2018-03-01
PH12019550022A1 (en) 2019-12-02
EA201890841A1 (ru) 2018-09-28
WO2018033227A8 (en) 2019-01-24
HK1258712A1 (zh) 2019-11-15
AU2017313164A1 (en) 2018-05-10
MA42964A (fr) 2018-08-01
US20190290689A1 (en) 2019-09-26
HK1259143A1 (zh) 2019-11-29
EA201890840A1 (ru) 2018-09-28
US20190231816A1 (en) 2019-08-01
KR20190049690A (ko) 2019-05-09
SG11201900866YA (en) 2019-02-27
CN108348549A (zh) 2018-07-31
AU2017313163A1 (en) 2018-05-10
MX2019001948A (es) 2019-05-15
MX2019001949A (es) 2019-05-15
CR20190091A (es) 2019-05-07
TW201806606A (zh) 2018-03-01
CO2019001265A2 (es) 2019-02-28
PH12019550017A1 (en) 2019-11-04
AU2017313163B2 (en) 2019-01-03
KR20190046793A (ko) 2019-05-07
PE20190627A1 (es) 2019-04-26
CA3033899A1 (en) 2018-02-22
US20210290671A1 (en) 2021-09-23
CL2019000419A1 (es) 2019-07-05
WO2018033227A1 (en) 2018-02-22
IL259006A (en) 2018-07-31
SG11201901085RA (en) 2019-03-28
CR20190139A (es) 2019-06-03
IL259007B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
CL2019000419A1 (es) Preparación farmacéutica anti-envejecimiento
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
MX2015012437A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
MX2020001443A (es) Sistema y métodos de extracción fitoquímica para extraer fitoquímicos de plantas incluidas las plantas de la familia cannabaceae sensu stricto.
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
BR112016021820A2 (pt) Método para revestimento de um substrato de filtro compreendendo uma pluralidade de canais
MX357392B (es) Ensayos basados en interrogatorios celulares y uso de los mismos.
MX389773B (es) Aparato, sistema y metodo de inspeccion de forma de cigueñal.
EP3624242C0 (en) DIRECT LIQUID FUEL CELL POWER GENERATION DEVICE
PE20121018A1 (es) Sistema de automatizacion integrado
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
AR100385A1 (es) Aparato para retirar huevos de portadores de huevos, y procedimiento asociado
CO2017000056A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
CL2012002669A1 (es) Metodo para la preparacion de un combustible para motores de encendido por compresion, que comprende los pasos que consisten en proporcionar una mezcla de un combustible de hidrocarburo primario que comprende uno o mas alcoholes; y deshidratar en la mezcla a su eter correspondiente y agua.
ECSP15002095A (es) Formulación farmacéutica
AR095583A1 (es) Recipiente que tiene un indicador de uso
BR112017009465A2 (pt) processos para recuperar álcoois
AR102396A1 (es) Procedimiento para formar una manga en un recipiente
CL2016003351A1 (es) Lipido que comprende ácido docosapentanoico
BR112015010249A2 (pt) aparato e método para a obtenção de amostras de fluido de formação
NZ730713A (en) Dissolution testing of hydrophobic active pharmaceutical ingredients such as avermectins with or without pyrantel
MX2017013345A (es) Metodos y sistemas para proporcionar una plataforma de comunicacion en linea para una comunidad de personas objetivo.
CO7151536A2 (es) Bioensayos con calidad controlada basados en células para productos nutricéuticos y medicinales
AR101088A1 (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano
MX2015012542A (es) Partículas de resinato de fenilefrina y su uso en formulaciones para productos farmacéuticos.